Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02719613
Title Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb

multiple myeloma


Bortezomib + Dexamethasone + Elotuzumab + Lenalidomide

Age Groups: senior | adult
Covered Countries USA | CAN

No variant requirements are available.